JOP20220104A1 - نظام تجريع لعوامل مضادة لـ dll3 - Google Patents
نظام تجريع لعوامل مضادة لـ dll3Info
- Publication number
- JOP20220104A1 JOP20220104A1 JOP/2022/0104A JOP20220104A JOP20220104A1 JO P20220104 A1 JOP20220104 A1 JO P20220104A1 JO P20220104 A JOP20220104 A JO P20220104A JO P20220104 A1 JOP20220104 A1 JO P20220104A1
- Authority
- JO
- Jordan
- Prior art keywords
- dll3
- agents
- dosing regimen
- sclc
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يتعلق الاختراع الحالي بتوفير طريقة لمعالجة سرطان موجب DLL3 أو SCLC، تشمل إعطاء خاضع بحاجة إليها عامل مضاد لـ DLL3 بجرعة بين حوالي 0.3 مجم إلى حوالي 100 مجم أو بين حوالي 3 مجم إلى حوالي 200 مجم، مرة واحدة كل أسبوعين. يتم أيضاً الكشف عن التجريع التدريجي للعامل المضاد لـ DLL3 لمعالجة SCLC.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19208214.7A EP3819312A1 (en) | 2019-11-10 | 2019-11-10 | Dosing regimen for anti-dll3 agents |
US202063078131P | 2020-09-14 | 2020-09-14 | |
PCT/US2020/059052 WO2021092134A1 (en) | 2019-11-10 | 2020-11-05 | Dosing regimen for anti-dll3 agents |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220104A1 true JOP20220104A1 (ar) | 2023-01-30 |
Family
ID=68531385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0104A JOP20220104A1 (ar) | 2019-11-10 | 2020-11-05 | نظام تجريع لعوامل مضادة لـ dll3 |
Country Status (14)
Country | Link |
---|---|
US (1) | US20230174643A1 (ar) |
EP (2) | EP3819312A1 (ar) |
JP (1) | JP2023501375A (ar) |
KR (1) | KR20220097470A (ar) |
CN (1) | CN114746117A (ar) |
AR (1) | AR120399A1 (ar) |
AU (1) | AU2020377981A1 (ar) |
CA (1) | CA3156229A1 (ar) |
IL (1) | IL292463A (ar) |
JO (1) | JOP20220104A1 (ar) |
MX (1) | MX2022005596A (ar) |
TW (1) | TW202128762A (ar) |
UY (1) | UY38948A (ar) |
WO (1) | WO2021092134A1 (ar) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023164474A1 (en) * | 2022-02-23 | 2023-08-31 | Amgen Inc. | Cancer treatment targeting dll3 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100508289B1 (ko) | 1998-04-21 | 2005-08-17 | 마이크로메트 에이지 | Cd19×cd3 특이 폴리펩티드 및 그의 용도 |
ATE493441T1 (de) | 2003-10-16 | 2011-01-15 | Micromet Ag | Multispezifische deimmunisierte cd3-bindende moleküle |
SI2155783T1 (sl) | 2007-04-03 | 2013-10-30 | Amgen Research (Munich) Gmbh | Medvrstno specifiäśna cd3-epsilon vezavna domena |
EP3093294A1 (en) * | 2012-02-24 | 2016-11-16 | Stemcentrx, Inc. | Dll3 modulators and methods of use |
GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
TW202346349A (zh) * | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
PE20181292A1 (es) * | 2015-08-20 | 2018-08-07 | Abbvie Stemcentrx Llc | Conjugados anticuerpo anti-dll3-farmaco y metodos de uso |
EP3341009A4 (en) * | 2015-08-28 | 2019-05-01 | Amunix Pharmaceuticals, Inc. | CHIMERIC POLYPEPTIDE ASSEMBLY AND METHODS OF PREPARING AND USING THE SAME |
RU2019104889A (ru) * | 2016-08-02 | 2020-09-04 | Вистерра, Инк. | Генно-инженерные полипептиды и их применение |
WO2018107116A1 (en) * | 2016-12-09 | 2018-06-14 | Abbvie Stemcentrx Llc | Methods of reducing toxicity of antibody drug conjugates, and compositions produced thereby |
SG11201909547TA (en) * | 2017-05-05 | 2019-11-28 | Amgen Inc | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
-
2019
- 2019-11-10 EP EP19208214.7A patent/EP3819312A1/en active Pending
-
2020
- 2020-11-05 CA CA3156229A patent/CA3156229A1/en active Pending
- 2020-11-05 WO PCT/US2020/059052 patent/WO2021092134A1/en unknown
- 2020-11-05 UY UY0001038948A patent/UY38948A/es unknown
- 2020-11-05 TW TW109138598A patent/TW202128762A/zh unknown
- 2020-11-05 AU AU2020377981A patent/AU2020377981A1/en active Pending
- 2020-11-05 CN CN202080079658.XA patent/CN114746117A/zh active Pending
- 2020-11-05 KR KR1020227018942A patent/KR20220097470A/ko unknown
- 2020-11-05 MX MX2022005596A patent/MX2022005596A/es unknown
- 2020-11-05 AR ARP200103072A patent/AR120399A1/es unknown
- 2020-11-05 EP EP20886079.1A patent/EP4054636A4/en active Pending
- 2020-11-05 JO JOP/2022/0104A patent/JOP20220104A1/ar unknown
- 2020-11-05 JP JP2022526118A patent/JP2023501375A/ja active Pending
- 2020-11-05 IL IL292463A patent/IL292463A/en unknown
- 2020-11-05 US US17/775,520 patent/US20230174643A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
UY38948A (es) | 2021-05-31 |
CN114746117A (zh) | 2022-07-12 |
AR120399A1 (es) | 2022-02-09 |
IL292463A (en) | 2022-06-01 |
EP3819312A1 (en) | 2021-05-12 |
TW202128762A (zh) | 2021-08-01 |
EP4054636A4 (en) | 2024-01-03 |
JP2023501375A (ja) | 2023-01-18 |
US20230174643A1 (en) | 2023-06-08 |
WO2021092134A1 (en) | 2021-05-14 |
CA3156229A1 (en) | 2021-05-14 |
KR20220097470A (ko) | 2022-07-07 |
AU2020377981A1 (en) | 2022-05-26 |
EP4054636A1 (en) | 2022-09-14 |
MX2022005596A (es) | 2022-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4272818A3 (en) | Thrombolytic agent for the treatment of thromboembolism | |
MX2020013557A (es) | Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo. | |
MX2019012884A (es) | Terapia de combinacion. | |
JOP20200156A1 (ar) | إيسكيتامين لعلاج الاكتئاب | |
MX2020005166A (es) | Uso de un antagonista de vegf para tratar trastornos oculares angiogenicos. | |
MX2023001468A (es) | Tratamiento de cancer de prostata. | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
BR112019003533A2 (pt) | terapia de combinação com inibidores de glutaminase | |
MX2022006533A (es) | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso del mismo. | |
MX2020012755A (es) | Regimenes de dosificacion del inmunoconjugado anti antigeno leucocitario (cd37). | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
AR119159A1 (es) | Tratamientos de angioedema | |
JOP20220092A1 (ar) | جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر | |
GEP20247585B (en) | Furoindazole derivatives | |
PH12020500099A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor | |
MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
MX2021006242A (es) | Formulaciones de capsula. | |
MX2022011651A (es) | Composicion farmaceutica para tratamiento de diabetes. |